Novo Nordisk A/S header image

Novo Nordisk A/S

NOVO B

Equity

ISIN DK0062498333 / Valor 129508879

Nasdaq Copenhagen Equities (2025-10-22)
DKK 343.45-3.24%

Novo Nordisk A/S
UMushroom community rating:

star star star star star
3.87 14 votes No rating yet
NegativeNeutralPositive

About company

Novo Nordisk A/S, founded in 1923 and headquartered near Copenhagen, Denmark, is a leading global healthcare company specializing in the development, manufacturing, and marketing of pharmaceutical products. The company is renowned for its extensive range of diabetes care solutions, including various insulin therapies and innovative treatments aimed at improving patient outcomes. In addition to diabetes, Novo Nordisk also focuses on other therapeutic areas such as obesity, hemophilia, and growth disorders, leveraging advanced biotechnology to address unmet medical needs. Committed to research and development, Novo Nordisk invests significantly in scientific advancements to maintain its position in the competitive biopharmaceutical industry. The company's long-standing dedication to improving health through sustainable and effective treatments underscores its role as a key player in the global healthcare market.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-57.1%1Y
-12.0%3Y
54.7%5Y

Performance

55.1%1Y
40.0%3Y
35.7%5Y

Volatility

Market cap

179545 M

Market cap (USD)

Daily traded volume (Shares)

5,447,680

Daily traded volume (Shares)

1 day high/low

645.6 / 626.4

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.87

14 votes
Performance:
starstarstarstarstar
3.39
Innovation:
starstarstarstarstar
3.93
Society:
starstarstarstarstar
3.93
Nature:
starstarstarstarstar
3.57
Daniel Brailsford
United Kingdom, 22 Oct 2025
star star star star star
1
Alexander Priess
Switzerland, 13 Oct 2025
star star star star star
GLP-1 drugs have a huge potential for our Society.
Adrian Eckert
Switzerland, 03 Oct 2025
star star star star star
idk

EQUITIES OF THE SAME SECTOR

dentalcorp Holdings Ltd
dentalcorp Holdings Ltd dentalcorp Holdings Ltd Valor: 111405816
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.09%CAD 10.90
Savaria Corp
Savaria Corp Savaria Corp Valor: 1385257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.02%CAD 21.70
Sienna Senior Living Inc
Sienna Senior Living Inc Sienna Senior Living Inc Valor: 28093100
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.67%CAD 19.48
Medtronic PLC
Medtronic PLC Medtronic PLC Valor: 25187155
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 95.90
ACELYRIN INC
ACELYRIN INC ACELYRIN INC Valor: 126441937
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 2.27
Oncopeptides AB
Oncopeptides AB Oncopeptides AB Valor: 35671972
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.17%SEK 5.08
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.29%CHF 104.74
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.11%GBP 17.81
Spire Healthcare Group PLC
Spire Healthcare Group PLC Spire Healthcare Group PLC Valor: 24881418
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.07%GBP 2.43
Shield Therapeutics PLC
Shield Therapeutics PLC Shield Therapeutics PLC Valor: 29778101
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.27%GBP 0.074